ABSTRACT
Relevance. The long-term leadership of ARVI pathogens determines their significance in the damage caused to both health and the economy of the country. Aim. To identify the features of the structure of ARVI during the emergence and widespread spread of SARS-CoV-2. Materials and methods. The article uses methods used in epidemiological surveillance of acute respiratory viral infections. Results and discussion. The results of the diagnostic available ARVI pathogens monitoring during epidemic seasons 2018-2021 are presented. The tendency of greater engagement of aged group 15 y.o. and older in epidemic process by morbidity and hospitalization due to SARI was shown. 49 818 nasal swabs from patients with influenza infection, 36 044 – with ARVI and 59 062 – with SARS-CoV-2 were tested. The top three in the structure of ARVI were INF, HEV-D and HRSV (in the 2018–2019 season);INF, SARS-CoV-2 and HEV-D (2019–2020);SARS-CoV-2, HEV-D and HPIV/HCoV (2020–2021). The activity of viral pathogens also differed: for HPIV, HAdV, HEV-D, HMPV, a decrease in activity was noted during the appearance of SARS-CoV-2 (2019–2020) and some of its growth in the following season;in relation to HRSV and INF-a decrease in activity during the last two seasons, and for INF – extremely low activity in the 2020-2021 season;the activity of seasonal HCoV even increased slightly. The data of genetic analyses of SARS-CoV-2 positive samples showed the heterogeneity of its population with a representative of variants (Alfa, Delta) as well as endemic for Russia and Moscow variants only. The recommended composition of influenza virus vaccines for use in the 2021–2022 northern hemisphere influenza season and in the 2022 southern hemisphere influenza season are presented due to their drift changeability. Conclusions. SARS-CoV-2 was influenced by the activity of ARVI pathogens with the almost complete displacement of influenza viruses from the circulation in the period 2020–2021. © Burtseva EI, et al.
ABSTRACT
Annualy, SARS occupy a leading position in terms of morbidity and the magnitude of the economic damage caused both in the world and in the Russian Federation. Currently, the most widespread pandemics are caused by the influenza A (H1N1) pdm09 virus and the new SARS-CoV-2 coronavirus, which occupy a common ecological niche and require studying the manifestations of the epidemic process of ARVI for further development of measures to improve epidemiological surveillance of this group of infections. Aim of the study was to investigate the current manifestations of the epidemic process of ARVI and influenza, including in the context of a new coronavirus infection (COVID–19) pandemic, on the territory of Russia and in Moscow. Materials and methods. The assessment of the long-term dynamics of the incidence of ARVI and influenza (from 1999 to 2021), as well as its age structure in the territory of the Russian Federation and in Moscow, was carried out. The main sources of information were: WHO: «The situation with COVID-19 in the European region», the domestic information portal Stopkoronavirus.rf, as well as data from Federal State Statistical Observation forms No. 2 and No. 6. Results. During the period 2013–2019, a strong positive correlation was revealed between the incidence rates of ARVI in the Russian Federation and Moscow (p = 0.8, with p < 0.05), which became negative with the spread of SARS-CoV-2: in the country, the incidence rate of ARVI increased by 11.5% in 2020 and 15.6% in 2021., in Moscow there was a decrease of 45.1% than the average in Russia, which could be due to the quality of differential diagnosis of ARVI and COVID-19. In 2021 the incidence rate of influenza decreased by more than 2 times in all Federal Districts of the country, with the exception of the capital region, where it became the maximum-65.9 per 100 thousand population in 2021 (against 14.1 in 2019). In the age structure of influenza incidence, as well as ARVI, for the period from 2019 to 2021. the child population prevailed with the highest rates in the age groups of 1–2 years and 3–6 years. As the circulation of SARS-Cov-2 decreased to 15–19%, the activity of influenza viruses and other pathogens of the ARVI group increased (from 0.7–3.0% during the developed pandemic to 5.6–6.6% at the stage of its decline), which indicates a pronounced interference of pathogens detected at the global level in the system of Global Hospital Surveillance for flu. Conclusion. The forecast for the upcoming epidemic season 2022–2023 largely depends on the spread of the new coronavirus SARS-CoV-2, as well as its variability and the emergence of new variants. Nevertheless, there may be a significant increase in the incidence caused by the influenza A(H1N1)pdm09 virus, whose high activity was recorded in the current epidemic season in a number of countries in the Southern hemisphere. © 2022, Numikom. All rights reserved.
ABSTRACT
The article notes features of the last epidemic season (2020-2021) in the form of extremely low activity of influenza viruses with SARS-CoV-2 remaining dominant in the etiological structure of acute respiratory viral infections. Presented own data indicating the heterogeneity of SARS-CoV-2 (Alpha, Delta, B.1.1.317, B.1.1.397, B.1.1.523) isolated from hospitalized patients was noted. An increase in the etiological role of bocavirus, alpha-coronavirus and metapneumovirus with a decrease in the frequency of parainfluenza viruses, adenoviruses, rhinoviruses and respiratory syncytial virus was established. An unusual shift of the period of maximum activity of respiratory syncytial virus to the 20th week was noted. Attention is paid to the need during the ongoing pandemic COVID-19 to fully immunize children as part of the National Immunization Calendar, also emphasized the role of mandatory annual vaccination against influenza. It is noted that the maximum protective effect of immunoprophylaxis of influenza acute and recurrent respiratory infections can be achieved with a combination of vaccination with bacterial lysates. The article presents a review of the literature and our data demonstrating the safety, good tolerability, and high clinical and immunological efficiency of polyvalent mechanical bacterial lysate for the prevention of acute and recurrent respiratory infections in children. It is shown that the use of polyvalent mechanical bacterial lysate during the prevaccination period makes it possible to substantially reduce the frequency of intercurrent infections, which reduces the number of temporary medical withdrawals and increases the coverage of vaccinations against influenza in organized groups to 85.1%. The role of trained immunity as one of the possible mechanisms providing nonspecific immunoprophylaxis during influenza vaccination and the use of bacterial lysates is discussed. © 2021, Remedium Group Ltd. All rights reserved.
ABSTRACT
Objective. Data of the clinical picture forms of the disease, management and diagnostic capabilities of patients with COVID-19 continue to be studied. Our study presents results from the analysis of clinical and laboratory parameters of patients with COVID-19 in the period May-June 2020, who were treated in an infectious diseases hospital in Moscow. Patients and methods. The analytical cohort included 444, 198 men, 246 women aged 18 to 95 years, who were identified with SARS-CoV-2 RNA. The severity of the disease was determined in accordance with the temporary clinical recommendations (version 6 effective April 28, 2020), NEWS. Results. The study of the clinical picture showed the variability of the spectrum of clinical manifestations of COVID-19. The most common symptoms were fever, weakness, myalgia, dry cough, shortness of breath, diarrhea. The severity of the infection was not associated with the patient's gender, but was significantly correlated with age and the presence of comorbid status, which included chronic lung diseases, obesity, diabetes mellitus, and cardiovascular diseases. Observations of patients with severe and extremely severe course revealed characteristic laboratory markers of severity. The main method of etiological diagnosis was the RT-PCR method for detecting SARS-CoV-2 RNA in the nasopharyngeal secret. To verify COVID-19, we used an additional PCR method, fecal testing for the detection of SARS-CoV-2 RNA. © 2021, Dynasty Publishing House. All rights reserved.
ABSTRACT
Background. Integrative epidemiological and etiological analysis of peculiarities of the development of the COVID-19 pandemic in different countries of the world is of significant scientific and practical interest in order to improve the preparedness of medical and social services during the upcoming pandemics. The purpose of the research. To determine the features of the epidemic process caused by a new coronavirus infection COVID-19, in all the diversity of its interaction with influenza viruses and other ARVI agents in the Russian Federation. Materials and methods. The studies were performed in the system of routine influenza surveillance by the Federal Center for Influenza and ARI at the Smorodintsev Research Institute of Influenza and the Center for Ecology and Epidemiology of Influenza at the National Center for Epidemiology and Microbiology named after N.F. Gamaleya, in cooperation with Regional Collaborating Base Laboratories in accordance with the Order of the Federal Service for Consumer Rights Protection Surveillance and Human Well-being No. 373 of March 31, 2005. Information on morbidity and hospitalization was provided by the erritorial Departments of Rospotrebnadzor. Information on the results of PCR detection of influenza and ARVI viruses, including SARS-CoV-2, was received from the «enters for Hygiene and Epidemiology" and was entered on-line into the electronic database of the Smorodintsev Research Institute of Influenza of the Ministry of Health of Russia. «AmpliSens reagent kits produced by the Central Research Institute of Epidemiology were used for PCR detection and subtyping of influenza A and B viruses, to identify ARVI agents, for PCR diagnosis of COVID-19 the kits certified in the Russian Federation of various producers were used. Results. It has been established that the annual epidemics of influenza, as well as the development of the second wave of the COVID-19 pandemic in the season 2020–2021 was preceded pronounced increase of incidence rate (55.0-67.9 per 10,000), associated with rhinoviruses activity, starting from the week 38 to week 43. 2020, which reached on the peak 23–29.0% of patients examined. The increase of COVID-19 activity in the fall of 2020 began from week 41 with the peak (26.6–31.3%) of detection in the period from the week 47.2020 to week 4. 2021. The duration and severity of COVID-19 diseases, requiring hospitalization, distinguished the SARS-CoV-2 pandemic from influenza epidemics/pandemics. Significant changes in the nature of the epidemic process were found in the analysis of the age structure of morbidity and hospitalization – their distinct decrease in children's age groups against the background of pronounced growth among patients of the age group 15–64 yrs and, especially, in elderly people ≥ 65 yrs. The incidence growth curves coincided in time with an increase in SARS-CoV-2 activity against the background of a decrease in the detection frequency of other ARVI pathogens, including influenza and RSV viruses, as a result of pronounced interference between pathogens. Interestingly, as the frequency of SARS-CoV-2 detection decreased to 15–19%, the activity of rhinoviruses, seasonal coronaviruses and metapneumoviruses began to increase again from 0.7–3.0% to 5.6–6.6%, which indicated the existence of a quantitative relationship between the interference indicators of SARS-CoV-2 with other ARI agents. It was most clearly manifested in relation to influenza and RSV viruses, which detection in general for the season dropped to 0.04% and 0.3% respectively. Conclusions. The phenomenon of interference of SARS-CoV-2 with other viral respiratory agents was established, based on the facts of a sharp suppression of the circulation of influenza viruses, respiratory syncytial virus and other ARVI pathogens during the period of active spread of the pandemic coronavirus. A distinctive feature of the SARS-CoV-2 pandemic, in comparison with influenza epidemics, was its long duration and the severity of the diseases caused by that virus. During the period of the andemic, a clear decrease in the incidence and hospitalization among children was revealed, with their pronounced growth in adults and, especially, in older people ≥ 65 years old. © 2021, Numikom. All rights reserved.
ABSTRACT
Due to the emergence of a new coronavirus infection COVID-19, scientists around the world are actively working on a vaccine against the SARS-CoV-2 coronavirus. At the same time, it is possible that existing medications can help in the fight against this disease. The local antiseptic drug benzidamine hydrochloride in the early stages of illness can prevent the virus from entering the lower respiratory tract and potentially reduce the severe illness associated with pneumonia and, as a result, reduce COVID-19-related hospitalizations, which can significantly reduce the burden on the health care system. The aim: to evaluate the antiviral activity of benzidamine hydrochloride against SARS-CoV-2 in vitro. Material and methods. Antiviral properties of benzidamine hydrochloride were studied in vitro in non-toxic concentrations on monolayer of Vero-E6 cells infected with pandemic strain of SARS-CoV-2 coronavirus in treatment and prophylactic scheme of the compound and virus administration. Results. Benzidamine hydrochloride has antiviral activity (15,0 mcg/ml), the efficiency of its antiviral action is directly proportional to the concentration of the substance. Conclusions. Taking into account very limited range of antiviral drugs with direct action on SARS-CoV-2 virus, the studied preparation can be used in complex therapy at early stages of the disease, which can prevent virus penetration into lower respiratory tract and potentially reduce the number of complications. © 2021, Numikom. All rights reserved.
ABSTRACT
Background: The effectiveness of barrier function of the respiratory mucosa largely depends on interferons type I (IFNs-α/β) and type III (IFNs-λ). The IFNs-λ forms the first level of innate immune protection. The single-nucleotide polymorphisms (SNPs) affecting IFN- λ3 production were found previously. The study aimed to investigate a putative association of SNPs rs8099917 T/G located upstream IFNL3 gene and rs12979860 C/T within IFNL4 gene with a risk of pneumonia developing after infection with respiratory viruses. Methods: The nasopharyngeal swabs, lavages, and blood samples from 318 patients infected with respiratory viruses were analyzed. Of these, 168 participants were shown to have community-acquired pneumonia, while the rest patients were diagnosed with bronchitis. The respiratory virus genomes were detected by real-time polymerase chain reaction (PCR) using commercially available kits. The DNA samples from all patients were used to detect SNPs rs8099917 T/G and rs12979860 C/T by real-time PCR using a commercially available kit. COVID-19 morbidity and mortality data were obtained from the WHO website. Results: No association was found between different rs8099917 allelic variants and the development of pneumonia. The rs12979860 TT genotype was significantly more often detected in patients with pneumonia (p = 0.039;OR = 2.400;95% CI 1.310 - 3.706). IFN-λ3 production has been early found to be maximal with rs12979860 TT genotype. An association was established between rs12979860 T allele frequency and COVID-19 mortality rate in 13 countries. Conclusions: The rs12979860 TT genotype is a genetic marker of increased risk of pneumonia after infection with respiratory viruses. High T allele frequency may be an indicator of a higher COVID-19 mortality rate. Patients with rs12979860 TT genotype have an increased risk of developing COVID-19 pneumonia.
ABSTRACT
Results of analysis of phylogenetic, virological, epidemiological, ecological, clinical data of COVID-19 outbreaks in Wuhan, China (PRC) in comparison with SARS-2002 and MERS-2012 outbreaks allow to conclude: - the etiological agent of COVID-19 is coronavirus (2019-CoV), phylogenetically close to the SARS-CoV, isolated from human, and SARS-related viruses isolated from bats (SARS-related bat CoV viruses). These viruses belong to the Sarbecovirus subgenus, Betacoronavirus genus, Orthocoronavirinae subfamily, Coronaviridae family (Cornidovirinea: Nidovirales). COVID-19 is a variant of SARS-2002 and is different from MERS-2012 outbreak, which were caused by coronavirus belonged to the subgenus Merbecovirus of the same genus; - according to the results of phylogenetic analysis of 35 different betacoronaviruses, isolated from human and from wild animals in 2002-2019, the natural source of COVID-19 and SARS-CoV (2002) is bats of Rhinolophus genus (Rhinolophidae) and, probably, some species of other genera. An additional reservoir of the virus could be an intermediate animal species (snakes, civet, hedgehogs, badgers, etc.) that are infected by eating of infected bats. SARS-like coronaviruses circulated in bats in the interepidemic period (2003-2019); - seasonal coronaviruses (subgenus Duvinacovirus, Alphacoronavirus) are currently circulating (November 2019 - January 2020) in the European part of Russia, Urals, Siberia and the Far East of Russia, along with the influenza viruses A(H1N1)pdm09, A(H3N2), and Ð, as well as six other respiratory viruses (HPIV, HAdV, HRSV, HRV, HBoV, and HMPV).